Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The Company develops Jakafi (ruxolitinib), a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera when there has been an inadequate response to or intolerance of hydroxyurea.

Company Growth (employees)
Type
Public
HQ
Wilmington, US
Founded
1991
Size (employees)
1,208 (est)+24%
Website
incyte.com
Incyte was founded in 1991 and is headquartered in Wilmington, US

Incyte Office Locations

Incyte has offices in Wilmington, Geneva, Milan, Madrid and in 6 other locations
Wilmington, US (HQ)
1801 Augustine Rd
Planegg, DE
9 Fraunhoferstraße
Milan, IT
Via Fabio Filzi 25/A
Amsterdam, NL
Paasheuvelweg 25
Madrid, ES
Plaza de la Encina, 10-11
Stockholm, SE
Barnhusgatan 3
Show all (10)

Incyte Financials and Metrics

Incyte Financials

Incyte's revenue was reported to be $1.5 b in FY, 2017
USD

Revenue (FY, 2017)

1.5 b

Net income (FY, 2017)

(313.1 m)

EBIT (FY, 2017)

(243.7 m)

Market capitalization (23-Feb-2018)

18 b

Cash (31-Dec-2017)

899.5 m
Incyte's current market capitalization is $18 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

354.9 m511.5 m753.8 m1.1 b1.5 b

Revenue growth, %

44%47%47%

R&D expense

581.9 m1.3 b

General and administrative expense

303.3 m366.4 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

85.1 m89.8 m99.6 m198.1 m159.3 m163 m187.6 m263.5 m246.3 m269.5 m384.1 m326.4 m

R&D expense

71.7 m75.6 m84.7 m88.5 m118.4 m112.4 m132.1 m156.8 m120.3 m143.2 m408 m201.8 m

General and administrative expense

26.4 m37 m40.9 m39.4 m44.9 m51.7 m47.6 m64.6 m66.8 m75.8 m87.2 m90.1 m

Operating expense total

98.3 m112.7 m125.8 m128.2 m166.2 m170.4 m187.7 m227.4 m201.7 m247.2 m517.4 m319.2 m
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

471.4 m452.3 m521.4 m652.3 m899.5 m

Accounts Receivable

35.4 m57.9 m114.5 m148.8 m266.3 m

Inventories

9.6 m20.5 m17.8 m4.1 m6.5 m

Current Assets

555.8 m699.2 m842.4 m994.2 m1.5 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

272.1 m436.6 m406.3 m382 m421.8 m439.7 m445.8 m657.6 m487.7 m580.1 m361.8 m451.8 m

Accounts Receivable

33.2 m46.4 m47.2 m109.6 m69.6 m75.1 m87 m101.3 m129.5 m131.5 m245 m169.5 m

Inventories

359 k347 k269 k402 k2.4 m1.9 m2.4 m1.3 m6.1 m4.1 m4 m2.9 m

Current Assets

333.7 m581.2 m577.1 m662.6 m692.1 m733 m757.9 m935.6 m792.1 m886.7 m819.2 m844.8 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    (83.1 m)(48.5 m)6.5 m104.2 m(313.1 m)

    Depreciation and Amortization

    58.4 m52.2 m

    Accounts Receivable

    35.6 m(23 m)114 m(23.9 m)(117.5 m)

    Inventories

    (6.6 m)(4.1 m)17.8 m4 m4.9 m
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    (22 m)(34 m)(36.9 m)59.3 m(18.4 m)(39.6 m)24 m34.4 m36.9 m(187.1 m)

    Accounts Receivable

    47.2 m109.6 m69.6 m75.1 m87 m101.3 m129.5 m131.5 m245 m

    Inventories

    269 k402 k2.4 m1.9 m2.4 m1.3 m6.1 m4.1 m4 m

    Accounts Payable

    27.3 m26.6 m26.6 m29.2 m27.4 m31.9 m40.7 m57.5 m86.3 m
      USDY, 2017

      Revenue/Employee

      1.5 m

      Financial Leverage

      1.4 x
      Show all financial metrics

      Incyte Market Value History

      Incyte Median Salaries

      Source: 40 public H-1B filings from Incyte

      Incyte's Web-traffic and Trends

      Incyte Online and Social Media Presence

      Incyte Company Life and Culture

      You may also be interested in